FDA Issues Priority Review Voucher for Rare Pediatric Disease Product ADZYNMA

Summary

The FDA has awarded a priority review voucher to Takeda Pharmaceuticals U.S.A., Inc. for its rare pediatric disease product ADZYNMA, following a review of the application against specific criteria.